Anti-TNIP2 Polyclonal Antibody is a Rabbit antibody targeting TNIP2. Anti-TNIP2 Polyclonal Antibody can be used in WB,IHC-P,IHC-Fr,IF.

IgG

Human,Rat (predicted:Mouse,Dog,Horse)

1. Tissue/cell: rat brain tissue; 4% Paraformaldehyde-fixed and paraffin-embedded;
Antigen retrieval: citrate buffer (0.01 M, pH 6.0), Boiling bathing for 15 min; Block endogenous peroxidase by 3% Hydrogen peroxide for 30 min; Blocking buffer (normal goat serum) at 37℃ for 20 min;
Incubation: Anti-TNIP2 Polyclonal Antibody, Unconjugated (TMAB-13648) 1: 200, overnight at 4°C, followed by conjugation to the secondary antibody and DAB staining
2. Sample: A431 Cell (Human) Lysate at 40 μg
Primary: Anti-TNIP2 (TMAB-13648) at 1/300 dilution
Secondary: HRP conjugated Goat-Anti-rabbit IgG at 1/5000 dilution
Predicted band size: 49 kD
Observed band size: 49 kD

WB: 1:500-2000; IHC-P: 1:100-500; IHC-Fr: 1:100-500; IF: 1:100-500

Polyclonal

KLH conjugated synthetic peptide: human TNIP2/ABIN2/TNFAIP3 interacting protein 2

Human

TNIP2

TNFAIP3-interacting protein 2

Inhibits NF-kappa-B activation by blocking the interaction of RIPK1 with its downstream effector NEMO/IKBKG. Forms a ternary complex with NFKB1 and MAP3K8 but appears to function upstream of MAP3K8 in the TLR4 signaling pathway that regulates MAP3K8 activation. Involved in activation of the MEK/ERK signaling pathway during innate immune response; this function seems to be stimulus- and cell type specific. Required for stability of MAP3K8. Involved in regulation of apoptosis in endothelial cells; promotes TEK agonist-stimulated endothelial survival. May act as transcriptional coactivator when translocated to the nucleus. Enhances CHUK-mediated NF-kappa-B activation involving NF-kappa-B p50-p65 and p50-c-Rel complexes.